Clinical Trial Update: Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial is evaluating the combination of bortezomib, fludarabine, and cyclophosphamide for recurrent mantle cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Cytoxan (cyclophosphamide)
• Fludara (fludarabine)
• Velcade (bortezomib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Mantle Cell Lymphoma Recurrent | Phase 1, Phase 2 | Status: UNKNOWN